MSD announced that it has acquired Prometheus Biosciences, Inc. which is now a wholly-owned subsidiary of MSD. Prometheus’ leading candidate product PRA-023 (now known as MK-7240), is a humanized monoclonal antibody being developed to treat immune-mediated diseases such as autoimmune disease, ulcerative colitis and Crohn’s disease.
This news comes shortly after the FDA accepted sBLA for Merck & Co., Inc.’s, Rahway, NJ, USA (known as MSD outside the US and Canada) KEYTRUDA® (pembrolizumab) plus chemotherapy for advanced or unresectable biliary tract cancer on 8 June 2023.